Generated by GPT-5-mini| chronic kidney disease | |
|---|---|
![]() https://www.scientificanimations.com/ · CC BY-SA 4.0 · source | |
| Name | Chronic kidney disease |
| Field | Nephrology |
| Synonyms | Chronic renal disease; Chronic kidney failure |
| Symptoms | Fatigue; edema; hypertension |
| Complications | Cardiovascular disease; anemia; bone disease |
| Onset | Progressive |
| Duration | Chronic |
| Causes | Diabetes mellitus; hypertension; glomerulonephritis |
| Diagnosis | Glomerular filtration rate; urine albumin |
| Treatment | Blood pressure control; dialysis; transplantation |
chronic kidney disease
Chronic kidney disease is a progressive disorder of renal function leading to reduced glomerular filtration and accumulation of metabolic wastes. It is managed across clinical settings by multidisciplinary teams and intersects with public health, nephrology, and transplant services. The condition contributes to global morbidity and mortality and drives resource use in health systems, requiring coordinated care pathways and preventive strategies.
Chronic kidney disease is defined by persistent reduction in glomerular filtration rate or markers of kidney damage for three months or more, and is staged to guide care by international bodies and specialty societies. Major clinical guidelines inform staging and management decisions across hospitals, clinics, and community programs coordinated with organizations focused on noncommunicable diseases. Patient pathways often involve primary care providers, nephrology units, and transplant centers collaborating with payers and regulators.
Patients may report fatigue, anorexia, cognitive changes, and pruritus as kidney function declines, which prompts referrals to specialty clinics and tertiary centers. Hypertension, peripheral edema, dyspnea from fluid overload, and uremic symptoms lead to presentations in emergency departments and inpatient wards overseen by multidisciplinary teams. Laboratory abnormalities such as anemia and electrolyte disturbances are detected by clinical laboratories and interpreted by pathologists and nephrologists.
Diabetes mellitus is the leading cause in many regions and drives referrals to endocrinology services and diabetes care programs. Longstanding hypertension contributes substantially and brings patients into contact with cardiology and vascular medicine. Glomerulonephritis, polycystic kidney disease, and obstructive uropathy arising from prostatic hypertrophy or urolithiasis involve urology and genetics services. Older age, family history, autoimmune disorders, infections, and exposure to nephrotoxins are additional risk factors considered by clinicians and public health authorities.
Progressive nephron loss from diverse insults leads to adaptive hyperfiltration in residual nephrons and glomerulosclerosis, processes described in renal physiology and pathology texts. Tubulointerstitial fibrosis, chronic inflammation, and vascular remodeling underlie progressive decline and are studied in laboratories and research institutes. Secondary complications such as mineral and bone disorder result from disrupted mineral metabolism regulated by endocrine organs and recognized in metabolic research.
Diagnosis relies on measurements of estimated glomerular filtration rate using serum creatinine assays standardized by reference laboratories and quality programs. Urinary albumin-to-creatinine ratio and imaging studies performed by radiology departments help establish cause and severity. Kidney biopsy interpreted by renal pathologists may be required in selected cases and results guide treatment decisions coordinated by nephrology services and multidisciplinary teams.
Management emphasizes control of blood pressure, glycemic control in diabetes, and reduction of albuminuria following recommendations from clinical guideline committees and professional societies. Pharmacologic therapies include renin–angiotensin system inhibitors and newer agents evaluated in clinical trials and recommended by guideline-producing organizations. Advanced kidney failure requires dialysis modalities provided in specialized units or home settings and kidney transplantation performed by transplant centers and surgical teams. Supportive care, anemia management, mineral metabolism correction, and cardiovascular risk reduction are delivered in outpatient clinics and hospital programs.
Prevalence varies by region and demographic factors and is monitored by global health agencies, national health institutes, and epidemiology research groups. Progression risk is influenced by baseline kidney function, albuminuria, comorbidities, and access to specialist care; outcomes include increased cardiovascular events and mortality tracked in cohort studies and registries. Health policy, resource allocation, and transplant availability affect long-term prognosis and are addressed by health ministries, international organizations, and advocacy groups.
Category:Kidney diseases